Insulin therapy in type 2 diabetes (workshop)
|
|
- Kerry Lyons
- 5 years ago
- Views:
Transcription
1 1 Insulin therapy in type 2 diabetes (workshop) Krzysztof Strojek, MD PhD Bruce H.R. Wolffenbuttel, MD PhD 2 Relevant relationships (last years) Bv. Sponsorship or research support Bv. Honorarium or other (financial) compensation. Disclosure statement BHRW (Company) names Eur. Committee: KP7 EU grant (Meerdere) DiabetesFonds NL Juvenile Diabetes Research Foundation NWO Min VWS, AZ, Econ Affairs Provinces Groningen, Friesland, Drenthe Nierstichting (Kidney Foundation) Zon MW MENZIS EASD / EFSD AstraZeneca Becton Dickinson Eli Lilly Thermo Fisher Novo Nordisk Roche Sanofi Aventis Boehringer Ingelheim Bayer The complete presentation can be downloaded from Treatment of type 2 diabetes in 199: with each step treatment gets more complex Case 1: a 6 yr old teacher Diet and exercise * 4 Sulphonylurea SU+metformin Insulin (± tablets) 4 A 6 year old male Type 2 diabetes since 1999, borderline hypertension, statin user, mildly obese Failing oral therapy (SU + metformin), HbA1c 8.9% FBG of 9 mmol/l, p.p. BG up to 1 mmol/l Teacher at a junior high school Sedentary work during the week, but likes to bicycle in the weekends Case 2: an elderly woman in a nursing home UKPDS epidemiologic study: better glycaemic control means fewer complications A 82 year old female Type 2 diabetes since 1989, hypertension, triple antihypertensives, myocardial infarction in 24, statin and aspirin user, mildly obese Failing oral therapy (SU + metformin), HbA1c 8.9% FBG of 9 mmol/l, p.p. BG up to 1 mmol/l Sedentary lifestyle Likes to go to the zoo with her grandchildren 6 Complications % % HbA1c = 33% eyes, kidney heart/bloodvessels 6, 7, 8, 9,, HbA 1c (%) ADA/EASD goals HbA1c < 7.% UKPDS
2 What do doctors want to achieve with? What is success? 7 Reduce hyperglycaemic complaints (if any) Achieve (near) normoglycaemia: BG between and 8 mmol/l Prevent complications Avoid hypoglycaemia, especially in the elderly Can be easily adjusted in specific circumstances driving car, eating out, on holidays Can be easily administered by nurse if in nursing home 8 For the patient: it is a simple treatment has no side effects I can eat and drink all no injections please, and no fingerpricks I don t know what hypo is, but surely do not want it I still want to visit my grandchildren my neighbour went blind after starting insulin 1. Bring some simplicity 2. Discuss misconceptions and misbelieves Insulin treatment options in type 2 diabetes Choices, choices, choices... 9 Prandial / Intensified Conventional Basal Prandial / Intensified Conventional Basal Short acting insulin Usually 2 injections Short acting insulin Usually 2 injections (analog) prandially + mix of short acting insulin (analog) +/ oral agents (analog) prandially + mix of short acting insulin (analog) +/ oral agents and long acting insulin and long acting insulin NPH insulin? Glargine / Levemir? Regular or analog? 2/7? 3/7? /? NPH insulin? Glargine / Levemir? Continue which oral agents? SU? Metformin? TZD? Choices, choices, choices... Once daily insulin: basal injection always combined with oral agents 11 Prandial / Intensified Short acting insulin (analog) prandially + Conventional Usually 2 injections mix of short acting insulin (analog) Basal more than 2 combinations of insulin and oral agents are possible; +/ oral agents 12 metformin 3 dd 8 mg* gliclazide 2 3 dd 8 mg NPH insulin? Glargine / Levemir? Regular or analog? and long acting insulin so be smart, use only a few starter regimens in your daily practice, and gain experience with them, 2/7? 3/7? /? NPH insulin? Glargine / Levemir? while adjusting when needed by the patient Continue which oral agents? SU? Metformin? TZD? * or 2 dd mg 2
3 13 Once daily insulin: basal injection always combined with oral agents metformin 3 dd 8 mg beneficial for weight gain and/or insulin dose may increase risk hypo 14 Twice daily insulin mixture: for instance Humalog Mix 2 R / NovoMix 3 R metformin 3 dd 8 mg gliclazide 2 3 dd 8 mg fast acting long acting * or 2 dd mg 1 Pre prandial insulin injections Insulin aspart/lispro fast fast fast acting Cán work, but frequently basal insulin needed 16 Insulin aspart/lispro Basal bolus : 4 injections daily NPH/ Glargine/Detemir fast fast fast acting long acting Insulin therapy regimen should take into account lifestyle and other activities Starter insulin regimen in type 2 diabetes vary across Europe Results from the INSTIGATE study % of patients basal only premixed only short acting only basal-bolus other Germany France UK Greece Spain Smith H, et al. Diabetologia 28; 1 (suppl. 1): S443 3
4 19 Q. You have started basal insulin therapy. How long does the 'effect' last? 2 Simple starter regimens need intensification over time: lessons from DURABLE study LM2 LisPro Mix 2 Glargine Probability p=.4 between treatment difference Months of Maintaining HbA 1c Goal < 7.% Wolffenbuttel BHR, et al. EASD 2 21 Q. Three different regimens: basal insulin twice daily mix 3 times daily fast acting. What do patients like the most? 22 4T: long term effects 82% need to add fast acting insulin Holman R, et al. NEJM T: intensified insulin regimen gives lowest HbA1c Basal Biphasic Prandial 7.6±1. % 7.3±.9 %, p=.8 vs. biphasic 7.2±.9 %, p<.1 vs. biphasic/prandial Δ.8±1. 1.3± ±1. 24 but at a price of higher body weight, insulin dose and hypoglycaemia Change in BW (kg) Insulin dose (U) Hypo & HbA1c (%) P<.1 Basal Biphasic Prandial +1.9 ± (28 to 72) ± 4. * 48 (3 to 71).7 * +.7 ± 4.6 * # 6 (34 to 78) 12. * # & Grade 2 events/patient/year Time (months) adapted from: N Engl J Med 27; 37: N Engl J Med 27; 37:
5 NICE: better postprandial BG control with ultrafast acting insulin analog Q. Do postprandial BG values matter? 26 FBG (mmol/l) PPBG (mmol/l) 2 1 * * * * * HbA1c (%) Time (yrs) HbA1c 7. HbA1c Time (yrs) Time (yrs) * p< Japanese pat s w. T2DM 3 injections fast acting insulin, NPH if needed Regular (Actrapid) vs Insulin aspart (NovoRapid) Nippon ultrapid Insulin & diabetic Complications Evaluation (NICE) adapted from: Nishimura et al. Diabetologia 28 (A1349)... does reduce c.v. events!! (MI, angina, PCI/CABG, TIA/CVA) But all patients had short duration of diabetes! Insulin treatment options in type 2 diabetes 27 C.V. events (%) % HR.7 CI:.34.9 (p<.2) 28 Prandial / Intensified Short acting insulin (analog) prandially + Conventional Usually 2 injections mix of short acting insulin (analog) and long acting insulin Basal +/ oral agents Time (years) Summary of all studies What are the main differences? Nippon ultrapid Insulin & diabetic Complications Evaluation (NICE) ClinicalTrials.gov NCT7172 adapted from: Nishimura et al. Diabetologia 28 (A1349) Some general issues on insulin regimens 1 Some general issues on insulin regimens 2 29 Long acting insulin analogs vs. NPH insulin: fewer hypo's with better HbA1c reduction, and less variation of fasting glucose 3 Prandial / Intensified (basal bolus) Conventional (premixed) Basal (NPH / long acting) Fast acting insulin analogs give better ppbg control than regular insulin Combination with metformin reduces insulin dose and mitigates BW increase HbA1c PPBG control better (if OA s continued) better (3 % HbA1c 7.%) worse Simple starter insulin regimens need intensification within 14 to 16 months, because of HbA1c increase regimen difficult hypoglycaemia +++ slightly difficult ++ easy, continue OA s + weight gain complications???
6 In 28, several long term clinical trials have reported their results 31 Q. Is intensified harmful? 32 What did they study? VADT 1. Can strict glycaemic control prevent cardiovascular complications? 2. Do we need to aim for HbA1c < 6.%? Macrovascular outcomes in ACCORD and ADVANCE: no difference between 'standard' and 'intensive' ACCORD showed high incidence of severe hypo trial stopped early because of side effects with intensive R/ p<.1 intensive control arm stopped prematurely because of increased C.V. events Speculations on cause of increased mortality in ACCORD is answered in VADT substudy Diabetes duration determines the risk of c.v. events during intensive (insulin) therapy (VADT) 3 Coronary artery calcification (CAC) score measured in 31 VADT participants 4% had CAC score > 4 CAC predicted new events Intensive therapy is especially effective in low CAC score % with c.v. event p<.1 std int < > CAC score 36 Risk 2 1 Benefit Deleterious Diabetes duration (yrs) CAC=, (very high risk) RACED: Risk Factors, Atherosclerosis and Clinical Events in Diabetes adapted from: Reaven. ADA presentation VADT, June 28 adapted from: Duckworth. ADA presentation VADT, June 28 6
7 37 Diabetes metabolic syndrome Genes? 38 Hazard ratios for all cause mortality by HbA1c deciles oral combination insulin based therapies low grade inflammation treatment upregulation HPA -axis/ GH dietary factors? hypoglycaemia metabolic imbalances cardiac arrhythmia adverse effect on vasculature which is already damaged in diabetes acceleration of atherosclerosis ischaemia C.V. event Primary care database on diabetes treatment in England: 1. Those on insulin had more c.v. disease & renal insufficiency 2. With very low HbA1c, we observe an increase in mortality Currie CJ, et al. Lancet 2; 37: Same HbA1c, different numbers of hypoglycaemia 39 Patient A: type 2 diabetes for years metformin 2dd mg, sitagliptin mg HbA1c 6.% no hypoglycaemia Patient B: type 2 diabetes for 8 years metformin 2dd mg, glargin 44 U at bedtime HbA1c 6.% 3 mild hypo's per week 1 severe hypoglycaemia per person per year 4 Q. Are we really sure about its safety? We know a lot about metabolic effects of various diabetes treatments, but almost nothing about their long term effects!! Insulin: the best there is?? Higher insulin dose is associated with more atherosclerosis 41 Insulin treatment in type 2 diabetes is associated with: Better glycaemic control Small improvements in dyslipidaemia Increase in body weight Hypoglycaemia 42 but also: Heart rhythm disturbances 1 Increase in BP 2,3 Inflammation of the vascular wall 4, Mitogenic effects 6,7 Inflammation of adipose tissue 8 related to hypoglycaemia sodium retention obesity & insulin resistance insulin growth factor influx macrophages 1. Chow E, et al. Diabetes 214; 63: ; 2. Kanoun F, et al. Diabetes Metab. 21; 27: Sarafidis PA, Am J Nephrol 27; 27: 44 4; 4. Andersson CX, et al. Diabetes Metab Res Rev 28; 24: Barrett EJ, Liu Z. Rev Endocr Metab Disord 213; 14: 21 7; 6. Lundby A, et al. J Appl Toxicol doi:.2/jat Rostoker R, et al. Endocr Relat Cancer 21; 22: 14 7; 8. Jansen HJ, et al, Diabetologia 213; 6: Muis MJ et al. Atherosclerosis 2; 181:
8 Insulin use and dose is associated with increased risk of CVD and mortality Insulin use and dose is associated with increased risk of CVD and mortality 43 In T2DM, exogenous insulin may be associated with increased risk of diabetes related complications 44 In T2DM, exogenous insulin may be associated with increased risk of diabetes related complications Event rate (per 1, person years) Low dose Mid dose High dose Event rate (per 1, person years) Low dose Mid dose High dose Insulin + Insulin only and Insulin metformin insulin+metformin only All cause mortality Insulin + metformin Insulin only and insulin+metformin Combined endpoint Insulin only Insulin + Insulin only and Insulin metformin insulin+metformin only All cause mortality Insulin + metformin Insulin only and insulin+metformin Combined endpoint Insulin only Currie CJ, et al. J Clin Endocrinol Metab 213;98: Currie CJ, et al. J Clin Endocrinol Metab 213;98: Q. Who is (besides the patient) the most important person when starting? 46 Address patient reluctance: patients who perform self monitoring of blood glucose will more rapidly switch from tablets to insulin Factors for success in Once daily insulin: basal injection always combined with oral agents 47 Education: discuss expectations discuss 'insulin resistance' and teach SMBG discuss weight gain and hypoglycaemia (and how to avoid it) 48 metformin 3 dd 8 mg (2 dd mg) gliclazide 2 3 dd 8 mg Tailoring: choose two or three starter regimens, gain experience with them, and adjust if needed encourage insulin regimen which 'fits' the patient and can be adjusted to long term goals and lifestyle Insulin therapy = personalized medicine 1. continue oral agents 2. add 8 E long acting insulin at bedtime of breakfast 3. titrate on fasting BG 4. if hypoglycemia, reduce sulphonylurea dose. if daytime hyperglycemia, add 2nd injection of insulin 8
9 49 Twice daily insulin mixture: for instance Humalog Mix 2 metformin 3 dd 8 mg (2 dd mg) fast acting long acting Pre prandial insulin injections Insulin aspart/lispro fast fast fast acting 1. continue metformin 2. give 2/3 of insulin at breakfast and1/3 at dinner 3. titrate on BG before main meals / at bedtime, slower in the elderly 4. self monitoring mandatory. reduce dose in weekend when bicycling 1. continue metformin 2. give insulin at 4% breakfast, 2% lunch, 3% dinner 3. titrate on BG before main meals / at bedtime, slower in the elderly 4. self monitoring mandatory. frequently need for long acting insulin at bedtime 1 Basal bolus : maximal flexibility metformin 3 dd 8 mg (2 dd mg) 2 Insulin injection regimens in type 2 diabetes Continue oral agents Add long acting insulin bedtime Continue metformin Twice daily 2/7 mixture fast fast fast acting long acting Aspart/lispro NPH/ Glargine Add fast acting insulin when significant hyperglycemia Change % fast acting in mixtures when postprandial hyperglycemia Add 2nd fast acting insulin when significant hyperglycemia Add fast acting insulin at lunch when afternoon hyperglycemia 1. give 3 4% of insulin as long acting at bedtime 2. titrate on BG before main meals / at bedtime, later on p.p. BG 3. self monitoring mandatory 4. reduce dose when exercising / eating less Fast acting insulin before meals Long acting at bedtime Insulin injection regimens in type 2 diabetes 3 Basal Basal + 2/7 2/7 Biphasic 2/7 / Biphasic 4 Q. Is there an alternative to insulin therapy? 2/7 / Basal ++ Biphasic + long acting biphasic fast acting Multiple injections 9
10 Question to the audience Case 3. A diabetes problem in clinical practice perverted by reimbursement issues For a patient with type 2 diabetes, intolerant to metformin, failing gliclazide + sitagliptin, HbA1c 7.9%, BMI 3 kg/m 2, I would prescribe: 1. a GLP1 agonist like exenatide 2. basal insulin (glargine) 3. twice daily premix insulin (LisPro mix 2) 4. multiple daily insulin injections 6 Type 2 diabetes, 9 years, treated by G.P. Weight 9 kg BMI 3 kg/m2 intolerant to metformin gliclazide + sitagliptin simvastatin normal blood pressure, normal lipds HbA1c 7.9% What is the best treatment for me at this moment? Question to the audience The case of mrs. E., 9 years 7 For a patient with type 2 diabetes, intolerant to metformin, failing gliclazide + sitagliptin, HbA1c 7.9%, BMI 3 kg/m 2, I would prescribe: 1. a GLP1 agonist like exenatide 2. basal insulin (glargine) 3. twice daily premix insulin (LisPro mix 2) 4. multiple daily insulin injections 8 Type 2 diabetes Weight 9 kg BMI 3 kg/m 2 intolerant to metformin gliclazide + sitagliptin simvastatin normal blood pressure How is reimbursement of insulin and GLP1 agonists arranged in your country? In The Netherlands, this is only reimbursed when BMI > 3 kg/m 2 Goal: improving control but wants to loose weight The case of mrs. E., 9 years Woman, 9 years, type 2 diabetes 9 Type 2 diabetes Weight 9 kg BMI 3 kg/m 2 intolerant to metformin gliclazide + sitagliptin simvastatin normal blood pressure 6 Type 2 diabetes, since 6 yrs Weight 9 kg BMI 3 kg/m 2 intolerant for metformin; R/ gliclazide + sitagliptin simvastatin normal bloodpressure Goal: glycaemic improvement but wants to loose weight Does not consider insulin to be an option Goal: improving control but wants to loose weight start of exenatide bid, pays for it herself Euro per month Weight 7 kg (BMI 2) stop sitagliptin; start GLP1 rec. agonist, is paying this HERSELF Euro per month Weight 7 kg (BMI 2) No hypo s No side effects
11 Man, 7 years, type 2 diabetes Insulin or GLP1 agonist as a first step after failure on oral agents? 61 Type 2 diabetes, since 6 years Weight 114 kg BMI 3.6 kg/m 2 metformin & glimepiride; atorvastatin 3 BP lowering drugs Goal: glycaemic improvement bnu wants to loose weight (not gain it) Does not consider insulin a good option 62 1 patients DM2 age 3 7 years HbA 1c 7 11% (SU+MF) BMI 2 4 kg/m 2 Exenatide 2 dd mcg 2 dd mcg decrease dose of glimepiride start liraglutide 1.2 mg Weight 7 kg (BMI 33.4) stable medication dose! No hypo s No side effects Randomized study 13 countries Time (weeks) Novomix 3 2 dd sc Nauck M., et al. Diabetologia 27 Exenatide: lower body weight and postprandial BG Obesity a risk factor for many chronic disorders 63 Exenatide 64 Metabolic consequences Diabetes Cardiovascular disease Difference.4 kg Insulin Dynamic consequences Arthrosis/arthritis/gout Pulmonary complaints Sleep apnoea Esophageal reflux Cancer Various types of cancer Other Gall stones Alzheimer s disease Cognitive disturbances kg during GLP1 RA therapy = Outcome of car accidents fewer long-term sequelae?? Postoperative complications Possible scenarios regarding body weight benefit of GLP1 agonists New drugs are more expensive than old drugs 6 Body weight (kg) 9 9 Insulin therapy (weight ) Scenario 1 Scenario 2 (best one) Scenario 3 66 Price per month: SU: 3 4 Euro, Metformin: 3 4 DPP4 i & SGLT2 remmer: 4 Insulin: 7 GLP1 RA: Time (years) Short term costs vs long term benefits Possible benefits of long term reduction of excess body weight: 'Metabolic' / 'Dynamic' / 'Cancer' / 'Other'? Miele LG 11
12 Obesity a risk factor for many chronic disorders QALY vs. Costs 67 Can a 1 kg reduction of body weight reduce weight related morbidities? Metabolic consequences Diabetes Cardiovascular disease Dynamic consequences Arthrosis/arthritis/gout Pulmonary complaints Sleep apnoea Esophageal reflux Cancer Various types of cancer Other Gall stones Alzheimer s disease Cognitive disturbances Outcome of car accidents Postoperative complications 68 Expected QALYs prior to the first event A % Men 7% Expected medication cost per QALY (USD/QALY) Δ 6.% B Women 7% 6.% met+sulf+insulin % met+dpp IV+insulin met+glp 1+insulin met+insulin Expected medication cost per QALY (USD/QALY) QALYs vs. cost incurred by the four different treatment regimens as a function of glycemic control goal. Comparison of the expected QALYs vs. the expected medication cost per QALY incurred from diagnosis to first event (diabetes related complication or death) for men (A) and women (B). Each of the four treatments is compared as the glycemic control goal is varied from 6.% (48 mmol/mol) to 8% (64 mmol/mol). Results are presented using HbA1c of 6.% (48 mmol/mol) ( ), 7% (3 mmol/mol) ( ), and 8% (64 mmol/mol) ( ) as the glycemic control goal Zhang Y, et al. Diabetes Care 214;37: Making decisions in type 2 diabetes Progression of type 2 diabetes makes treatment choices / regimens more complicated 69 second line drug features 7 Failure on oral agents (OA) Lifestyle intervention (healthy food, weight reduction, physical activity) Metformin (metabolic control, less c.v. events, no hypoglycaemia, no weight increase Sulphonylurea Glinides Thiazolidines α GIucosidase inh. DPP 4 inhibitors GLP1 agonists hypo, weight gain hypo, safe in renal insuff. edema, c.v.d., bladder pp. BG, GI side effects no hypo, neutral weight injections, weight loss MF+OA+ GLP1ag MF+GLP1ag+ basal insulin MF+OA+ basal insulin MF+PreMix Insulin Insulin injections, weight gain, BG measurements MF+GLP1ag +BBT (?) Not approved yet MF+ BasalBolus Take home messages on 71 Intensive BG lowering: dangerous in long term diabetics and those with (severe) c.v. disease Long acting analogs vs. NPH insulin: fewer hypo's with better HbA1c reduction, and less variation of fasting glucose Fast acting analogs: better ppbg control than regular insulin, which may reduce c.v. complications Intensive insulin treatment: more hypoglycaemia, weight gain Simple starter insulin regimen: intensification within 14 to 16 months, because HbA1c increase 12
GLP1 receptor agonists. current status of development. Treatment of type 2 diabetes: a stairway to heaven? Disclosure statement
GLP1 receptor agonists: current status of development Bruce H.R. Wolffenbuttel, internist endocrinologist University Medical Center Groningen Dept. of Endocrinology: www.umcg.net Blog: www.gmed.nl Twitter:
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationInitiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital
Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationInsulin and Post Prandial
Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationCase Study: Competitive exercise
Case Study: Competitive exercise 32 year-old cyclist Type 1 diabetes since age 15 Last HbA1 54 No complications and hypo aware On Humalog 8/8/8 and Levemir 15 Complains about significant hypoglycaemia
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationNMQF. Washington DC 2014
NMQF Washington DC 2014 ACE/AACE Treatment Algorithm Jaime A. Davidson, MD, FACP, MACE Prof. of Medicine Division of Endocrinology, Diabetes and Metabolism President WorldWIDE Diabetes Advisor to the AACE
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationWhen and how to start insulin therapy in type 2 diabetes
When and how to start insulin therapy in type 2 diabetes Anne Kilvert MD, FRCP Most patients with type 2 diabetes will eventually require insulin due to the progressive decline in betacell function. Dr
More informationInsulin Therapy Management. Insulin Therapy
Insulin Therapy Management Insulin Therapy Contents Insulin and its effect on glycemic control Physiology of insulin secretion Insulin pharmacokinetics and regimens Insulin dose adjustment for pregnancy
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationInsulin use in Type 2 Diabetes
Insulin use in Type 2 Diabetes 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo Nordisk - Sanofi Aventis - MSD -
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationWhat s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy
What s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy 2013 Rocky Mountain/ACP Internal Medicine Conference November 15, 2013 David C.W. Lau, MD, PhD,
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationADVANCE Endpoints. Primary outcome. Secondary outcomes
ADVANCE Trial-NEJM 11,140 type 2 patients with h/o microvascular or macrovascular disease or 1 vascular disease risk factor Control A1c to 6.5% vs standard tx Intensive arm received gliclazide XL 30 to
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationFasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period
Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationCurrent Clinical Practice Guideline for Diabetes Management
Current Clinical Practice Guideline for Diabetes Management Chaicharn Deerochanawong M.D. Professor of Medicine, i Rangsit Medical University it Diabetes and Endocrinology Unit Department of Medicine Rajavithi
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More information